Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Defining Licensing Success

As of the Cummins license signing on 10/26/10, "Eighty global companies" had licensed the MMP.

On 2/3/11, PTSC released a PR that indicated that

"The TPL Group, and Alliacense announced today that during December 2010 and January 2011, MMP Patent Portfolio licenses were entered into with several companies in the telecommunications and industrial equipment industry segments."

Depending on the definition of several, that should mean anything from 3 companies to perhaps 7 or 8.

I thought I read a PACER or other document PRIOR to the Stryker license, that indicated that there were either 85 or "more than 85" licensees.

And then on 5/23/11, PTSC PR'd the Stryker license.

IF WE CAN BELIEVE THE OFFICIAL PTSC & ALLIACENSE PR's, (remember by agreement PTSC must approve TPL/Alliacense PR's just as they must approve PTSC's PR's) , it seems that since 10/26/10, at least 4 and more likely 6 or more companies have licensed the MMP. Not counting the Stryker license, those licenses have brought in at least $7.44M in MMP revenue to PDS according to PTSC's SEC Filings. Is $7.44M for 3 licenses successful? How 'bout for 8 licenses?

Obviously Chuck Moore expects MORE. Wonder what PTSC BOD and management would consider successful? Perhaps to them, this is successful since they've gotten their paychecks again this month.

Share
New Message
Please login to post a reply